Background {#S0001}
==========

Esophageal cancer (EC) is a common cancer and remains an integral cause of cancer-related deaths worldwide. Esophageal squamous cell carcinoma (ESCC) is the predominant subtype of EC in Asia and Africa, accounting for approximately 90% cases.[@CIT0001] Curative surgical therapy is the main treatment for cases of localized EC. However, in up to 75% cases, EC is too advanced for curative surgical therapy at the initial diagnosis.[@CIT0001] For such advanced regional and distant metastases cases, chemoradiotherapy is recommended in the National Comprehensive Cancer Network guideline and performed in clinical practice.[@CIT0002]

Esophageal perforation (EP) is a severe and life-threatening side effect during and after esophageal RT. Some studies revealed that the imbalance of tumor regression and normal tissue repair is the main cause of EP.[@CIT0003] Despite a 5--10% incidence rate of EP, it is associated with a poor prognosis and a high mortality rate.[@CIT0004],[@CIT0005] In this case, the risk factors that accurately predict EP before treatment play a crucial role in the selection of optimal treatment for ESCC. Some studies[@CIT0006]--[@CIT0008] demonstrated that nutritional status, T stage, extracapsular lymph nodes involving the esophagus (ECLNIE), etc. are independent prognostic factors of EP.

However, the abovementioned studies about the risk factors of EP were mainly single-center retrospective studies and have not yet reached a consensus. Moreover, the baseline characteristics in those studies were not well balanced and comparable. Therefore, we aimed to analyze the risk factors for patients with EP occurring during or after radiotherapy for ESCC and performed propensity score-matched (PSM) analysis to balance the baseline characteristics and adjust for indication biases for assessing the impact of ECLNIE.

Methods {#S0002}
=======

Patients {#S0002-S2001}
--------

This study was approved by the Ethics Committee of Fujian Provincial Tumor hospital. Written informed consents were obtained from all participants before treatment, and all the information was anonymized before analysis. In total, 306 consecutive patients with ESCC between January 2016 and December 2017 criteria were recruited in the study. Patients with Karnofsky score ≥70 points, those with cytologically and histologically confirmed ESCC, those who had undergone treatment with intensity-modulated radiation therapy (IMRT) and/or platinum-based chemotherapy, those who had undergone thoracic CT scan and barium radiography 1 week prior to RT, to exclude those with EP, those without a history of malignant disease or serious internal diseases, and those in whom the cTNM stage was re-determined according to the 8th American Joint Committee on Cancer TNM staging system[@CIT0009] based on the clinical data were included. Patients who had undergone esophagectomy were excluded.

Radiotherapy and Chemotherapy {#S0002-S2002}
-----------------------------

In this study, 306 patients with ESCC received IMRT for esophageal tumors. The thoracic and abdominal parts were fixed using one vacuum pad. Imaging data were collected from computed tomography (CT) simulation scan and transmitted to a radiation therapy treatment planning system (Pinnacle; version 9.2, Philips Radiation Oncology System, Wisconsin, USA) to delineate the gross tumor volume, clinical tumor volume, and the organs at risk by an experienced radiation oncologist according to the criteria of tumor delineation of the National Comprehensive Cancer Network. Radiation was delivered using a medical linear accelerator (Trilogy; Varian Medical Systems, USA) at a dose of 1.8--2.3 Gy per fraction per day, 5 days a week. The chemotherapy regimen based on cisplatin was used. It included TP (paclitaxel 135 mg/m^2^ dL + cisplatin 25 mg/m^2^ dL^3^) and DP (docetaxel 75 mg/m^2^ dL + cisplatin 25 mg/m^2^ dL^3^). Carboplatin was used in case of intolerance to cisplatin.

Assessment of EP, ECLNIE, Niche Sign, and Necrotic Areas {#S0002-S2003}
--------------------------------------------------------

EP was assessed according to the following image manifestations observed on CT: a) gas in the mediastinum or the soft tissue of the mediastinum surrounding the esophagus; b) abscess cavity adjacent to the esophageal wall in the mediastinum or pleural space or; c) actual communication of the esophagus and the air--fluid collection in the adjacent mediastinum.[@CIT0010],[@CIT0011] EP was also assessed by leakage on iodine oil radiography.

ECLNIE was assessed based on the following image manifestations on the contrast-enhanced CT scan: extracapsular lymph node involvement in the esophageal wall deemed positive for the metastatic lymph node with irregular nodal boundaries, thickening of adjacent fascia, and apparent invasion of the esophagus tissue with or without adjacent organs[@CIT0012],[@CIT0013] ([Figure 1A](#F0001){ref-type="fig"} and [B](#F0001){ref-type="fig"}). The image was re-evaluated independently by two experienced image specialists in Fujian provincial tumor hospital. The image specialists were highly trained. The interobserver variability occurred, the image was transferred to the third image specialist for independently re-evaluating.Figure 1The contrast-enhanced CT scan shows extracapsular lymph node involvement in the esophageal wall deemed positive. The red arrows respectively show the extracapsular lymph node involved the normal esophagus (**A**) and esophageal carcinoma wall (**B**).

Niche sign was assessed based on the esophageal wall outline coating with barium or iodine oil.[@CIT0014] Necrotic area was assessed according to the low-density area of the tumor lesion in enhanced CT scan.[@CIT0010]

Definitions of Nutrition-Based and Inflammation-Based Indicators {#S0002-S2004}
----------------------------------------------------------------

The body mass index (BMI) was calculated as the body weight divided by the square of the body height. The prognostic nutritional index (PNI) was calculated by the serum albumin level +5\*absolute lymphocyte count. The neutrophil-to-lymphocyte ratio (NLR) was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count.

Methods and Parameters of CT Scanning {#S0002-S2005}
-------------------------------------

A Brilliance 256-slice spiral CT scanner (PHILIPS, Eindhoven, The Netherlands) was used for scanning, with the patient in the supine position with both arms above the head and using the following parameters: tube voltage 120 kV, tube current 300--350 mA, scanning collimator 1 mm, pitch 0.9, scanning layer thickness 5 mm, layer spacing 5 mm, reconstruction layer thickness 2.5 mm, and layer spacing 2 mm. The enhanced scanning used one high-pressure syringe to rapidly inject 100 mL of non-ionic contrast agent (iodohydrin) from the elbow vein (injection rate 3 mL/s). The scanning area started from the skull base to the fifth lumbar spine, the data of which were then transmitted into Vitrea 2 Workstation for multiwindow and multiplanar reconstruction. Two experienced radiologists in our hospital retrospectively evaluated the pretreatment thoracic CT scans. The diameter of the thickest part of the primary tumor on the CT scan image was identified as the esophageal thickness. Asymmetric luminal involvement on the CT scan image was identified as the eccentric wall thickness.

Surveillance and Statistical Analysis {#S0002-S2006}
-------------------------------------

All patients who agreed to participate in the study underwent regular follow-up imaging examinations including CT scan, and barium radiography or iodine oil radiography before radiotherapy, every 2 weeks during radiotherapy, as well as 1 and 3 months after radiotherapy. Patients with severe chest pain, fever, and cough were required to undergo immediate iodine oil radiography and thoracic CT scan. The study endpoint was the incidence of EP within 6 months of RT.

All recorded data were analyzed using SPSS (version 23.0, SPSS Inc., Chicago, IL, USA) and R (version 3.2.2). The continuous variables were converted into classification variables using the receiver operating characteristic (ROC) curve or clinical common parameters. The maximal Jordan index (sensitivity + specificity − 1) was used to determine the continuous variables in order to determine the optimal value for predicting EP. The Chi-square test or Fisher's exact test was used for univariable analysis. The clinical characteristics for univariable analysis were sex, age, BMI, smoking history, alcoholism history subclass, T stage, N stage, M stage, whether patients received chemotherapy, whether they received RT for the second time, tumor length, esophageal thickness, ECLNIE, eccentric wall thickness, necrotic area, niche sign by esophagogram before RT, NLR, and PNI. The variables that achieved statistical significance in the univariate analysis were entered into the multivariable analysis, which was performed using the binary logistic regression analysis (a logistic regression model). The odds ratio (OR) value and the corresponding 95% confidence interval (CI) were calculated using binary logistic analysis to evaluate the independent risk factors for PE. A P value \< 0.05 was considered statistically significant.

PSM analysis was used to compensate for the differences in baseline characteristics between the ECLNIE and Non-ECLNIE groups to confirm the risk of EP difference. First, all available patient and tumor variables were compared using the Chi-square test. Next, a propensity score was calculated using logistic regression with the imbalanced variables that were statistically significantly correlated with the incidence of EP on multivariable analysis. Finally, all analyses regarding the incidence of EP adjusted based on the generated propensity score were subsequently performed to compare the differences between the ECLNIE and Non-ECLNIE groups after matching. Caliper matching was performed on the propensity score (nearest available matching) by the minimal adjacent method of 1:1 pairing.

Results {#S0003}
=======

Patient Characteristics {#S0003-S2001}
-----------------------

A total of 306 patients (232 men and 74 women) who met the inclusion criteria were enrolled ([Table 1](#T0001){ref-type="table"}). EP was observed in 26 patients, with an incidence rate of 8.5%. EP occurred during radiotherapy in 14 patients, and 12 patients developed EP 1--13 weeks after completion of radiotherapy. The mean and median intervals of development of EP were 8 and 6 weeks, respectively. Of the 26 patients with EP, 8 patients had esophagotracheal fistula, whereas the remaining patients had esophagomediastinal fistula. In total, 21 patients had ECLNIE, with an incidence rate of 80.8%. Of 21 patients with EP had ECLNIE, 20 had a fistula in the site of the primary lesion, and 1 patient had a fistula in the site of extracapsular lymph node involving the normal esophageal wall. The partial response and stable disease of patients with EP were evaluated according to the RECIST criteria while eliminating the possibility of EP owing to tumor progression.Table 1Patients' Characteristics for 306 ESCC PatientsCharacteristicsNumber of Patients (%)**Gender** Male232 (75.8) Female74 (24.2)**Age** \<65151 (49.3) ≥65155 (50.7)**BMI** \<2098 (32) ≥20208 (68)**Smoking history** Yes188 (61.4) No118 (38.6)**Alcoholism history** Yes66 (21.6) No240 (78.4)**T stage** T14 (5.9) T218 (5.9) T3105 (34.3) T4179 (58.5)**N stage** N081 (26.5) N1155 (50.7) N257 (18.6) N313 (4.2)**M stage** M0225 (73.5) M181(26.5)**Esophageal perforation** Yes26 (8.5) No280 (91.5)

Risk Factors for EP in the Entire Cohort {#S0003-S2002}
----------------------------------------

The common clinical parameters, BMI and age, were dichotomized BMI \<20, ≥20, and age\<65 years, ≥65 years in this study. The rest of the continuous variables were dichotomized using the ROC curve to calculate the optimal cut-off value that was most significantly correlated with the risk of EP difference using the AUC. For tumor length, the AUC was 0.774 (95% CI 0.697--0.851). The optimal cutoff value was 6.45, and the sensitivity and specificity were 0.769 and 0.707, respectively ([Figure 2A](#F0002){ref-type="fig"}). For esophageal thickness, the AUC was 0.799 (95% CI 0.711--0.887). The optimal cutoff value was 1.75, and the sensitivity and specificity were 0.769 and 0.729, respectively ([Figure 2B](#F0002){ref-type="fig"}). For NLR, the AUC was 0.715 (95% CI 0.614--0.815). The optimal cutoff value was 2.34, and the sensitivity and specificity were 0.731 and 0.657, respectively ([Figure 2C](#F0002){ref-type="fig"}). For PNI, the AUC was 0.693 (95% CI 0.601--0.786). The optimal cutoff value was 47.85, and the sensitivity and specificity were 0.532 and 0.889, respectively ([Figure 2D](#F0002){ref-type="fig"}). According to the criteria of predictive ability, the indicators exhibited had better predictive ability toward EP.Figure 2ROC curve of (**A**) tumor length, (**B**) esophageal wall thickness, (**C**) NLR, and (**D**) PNI for predicting esophageal perforation.

Univariable analysis revealed that age (P = 0.011), BMI (P = 0.003), T4 stage (P = 0.005), tumor length (P \< 0.001), esophageal wall thickness (P \< 0.001), ECLNIE (P \< 0.001), necrotic areas (P \< 0.001), niche sign by esophagogram before RT (P \< 0.001), NLR (P \< 0.001), and PNI (P \< 0.001) were significantly associated with EP among patients with ESCC who received RT ([Table 2](#T0002){ref-type="table"}). Multivariable analysis demonstrated that age (P = 0.038), ECLNIE (P \< 0.001), esophageal wall thickness (P = 0.044), and niche sign by esophagogram before RT (P = 0.001) were independent risk factors for EP in ESCC ([Table 3](#T0003){ref-type="table"}).Table 2Univariate Analysis of 306 ESCC PatientsVariablesNon-PerforationPerforationP valueN=280N=26**Gender** Male209230.115 Female713**Age** \<65 years old132190.011 ≥65 years old1487**BMI** \<2083150.003 ≥2019711**Smoking history** Yes171170.666 No1099**Alcohol consumption history** Yes6150.762 No21921**T4 stage** Yes157220.005 No1234**N stage** N07830.071 N1--32022**M stage** 0208170.325 1729**Chemotherapy** Yes221180.253 No598**RT for the second time** Yes1100.608 No26926**Tumor length** ≤6.45cm1986\<0.001 \>6.45cm8220**Esophageal thickness** ≤1.75cm2046\<0.001 \>1.75cm7620**Extracapsular LN involving esophagus** Yes5421\<0.001 No2265**Eccentric wall thickness** Yes5220.164 No22824**Necrotic area** Yes8420\<0.001 No1966**Niche sign by esophagogram before RT** Yes3917\<0.001 No2419**NLR** ≤2.341827\<0.001 \>2.349819**PNI** ≤47.8513223\<0.001 \>47.851483[^2][^3] Table 3Multivariate Analysis of 306 ESCC PatientsFactorsβOR95% CIP value**Age** \<65years old ≥65years old−1.3940.2480.067--0.9250.038**BMI** \<20 ≥20--0.7370.4790.137--1.6780.25**T4 stage** Yes No-0.2530.7760.157--3.8430.756**Extracapsular LN involving esophagus** No Yes2.30510.0232.809--35.757\<0.001**Tumor length** ≤6.45cm \>6.45cm0.3461.4140.352--5.6860.626**Esophageal thickness** ≤1.75cm \>1.75cm1.5184.5651.039--20.0540.044**Necrotic area** No Yes0.8822.4160.697--8.3750.164**Niche sign** No Yes2.0347.6442.292--25.4900.001**NLR** ≤2.34 \>2.340.9822.6700.788--9.0490.115**PNI** ≤47.85 \>47.85--1.1890.3050.067--1.3780.123

Impact of ECLNIE on EP with PSM {#S0003-S2003}
-------------------------------

In total, 65 pairs consisting of 130 patients each from the ECLNIE group and the non-ECLNIE group were matched 1:1 by PSM. The clinical characteristics of the two groups did not differ significantly after PSM ([Table 4](#T0004){ref-type="table"}; [Figure 3](#F0003){ref-type="fig"}). Following PSM, the incidence of EP in the ECLNIE and non-ECLNIE groups was 21.54% (14/65) and 3.08% (2/65), respectively (P = 0.002).Table 4Clinical Characteristics of Patients Before and After MatchingCharacteristicUmamatched PatientsMatched PatientsECLNIE (N=75)Non-ECLNIE (N=231)PStd.DiffECLNIE (N=65)Non-ECLNIE (N=65)PStd.Diff**Gender** Male60 (80%)172 (74.46%)0.330.13253 (81.54%)51(78.46%)0.6610.077 Female15 (20%)59 (25.54%)12 (18.46%)14(21.54%)**Age** \<65 years old47 (62.67%)104 (45.02%)0.0080.36038 (58.46%)43(66.15%)0.3660.159 ≥65 years old28 (37.33%)127 (54.98%)27 (41.54%)22(33.85%)**BMI** \<2028 (37.33%)70 (30.3%)0.2570.14923 (35.38%)23(35.38%)10.00 ≥2047 (62.67%)161 (69.7)42 (64.62%)42(64.62%)**Smoking history** Yes48 (64%)140 (60.6%)0.60.07042 (64.62%)42(64.62%)10.00 No27 (36%)91 (39.4%)23 (35.38%)23(35.38%)**Alcohol consumption history** Yes18 (24%)48 (20.78%)0.5560.07714 (21.54%)15(23.08%)0.8330.037 No57 (76%)183 (79.22%)51 (78.46%)50(76.92%)**T4 stage** Yes58 (77.33%)121 (52.38%)\<0.0010.54149 (75.38%)52(80.0%)0.5270.111 No17 (22.67%)110 (47.62%)16 (24.62%)13(20.0%)**N stage** N01 (1.33%)80 (34.63%)\<0.0010.9621 (1.54%)0(0.00%)10.177 N1--374 (98.67%)151 (65.38%)64 (98.46%)65(100.0%)**M stage** 041 (54.67%)184 (79.65%)\<0.0010.55238 (58.46%)40(61.54%)0.7200.063 134 (45.33%)47 (20.35%)27 (41.54%)25(38.46%)**Chemotherapy** Yes64(85.33%)175(75.76%)0.0810.24455(84.62%)55(84.62%)10.000 No11(14.67%)56(24.24%)10(15.38%)10(15.38%)**RT for the second time** Yes1 (1.33%)10 (4.33%)0.2260.1811(1.54%)1(1.54%)10.000 No74 (98.67%)221 (95.67%)64(98.46%)64(98.46%)**Tumor length** ≤6.45cm35 (46.67%)169 (73.16%)\<0.0010.56233 (50.77%)36(55.38%)0.5980.093 \>6.45cm40 (53.33%)62 (26.84%)32 (49.23%)29(44.62%)**Esophageal thickness** ≤1.75cm40 (53.33%)170 (73.59%)0.0010.43037 (56.92%)34(52.31%)0.5970.093 \>1.75cm35 (46.67%)61 (26.41%)28 (43.08%)31(47.69%)**Eccentric wall thickness** Yes10 (13.33%)44 (19.05%)0.2590.15610 (15.38%)12(18.46%)0.6400.082 No65 (86.67%)187 (80.95%)55 (84.62%)53(81.54%)**Necrotic area** Yes42 (56.0%)62 (26.84%)\<0.0010.62035 (53.85%)29(44.62%)0.2930.185 No33 (44.0%)169 (73.16%)30 (46.15%)36(55.38%)**Niche sign** Yes25 (33.33%)31 (13.42%)\<0.0010.48416 (24.62%)15(23.08%)0.8370.036 No50 (66.67%)200 (86.58%)49 (75.38%)50(76.92%)**NLR** ≤2.3441 (54.67%)148 (64.07%)0.1450.19236 (55.38%)37(56.92%)0.8600.031 \>2.3434 (45.33%)83 (35.93%)29 (44.62%)28(43.08%)**PNI** ≤47.8546 (61.33%)109 (47.18%)0.0330.28738 (58.46%)34(52.31%)0.4800.124 \>47.8529 (38.67%)122 (52.81%)27 (41.54%)31(47.69%) Figure 3Dot-plot of standardized mean differences of all covariates between the pre-matched and matched groups.

Discussion {#S0004}
==========

EP is a serious and life-threatening side effect during and after radiotherapy in patients with ESCC. Despite a low incidence rate, EP is associated with a poor prognosis and a high mortality rate. Hence, prediction of high-risk groups before treatment is crucial for the selection of the optimal treatment method. Some recent studies have revealed some risk factors including ECLNIE for EP. However, these are mainly single-center retrospective studies that have not yet reached a consensus, and the baseline characteristics for EP in these studies are not well balanced. In this study, we comprehensively analyzed the risk factors including nutritional status, systemic inflammatory status, TNM stage, and image indicators, and performed PSM analysis to balance the baseline characteristics. We retrospectively studied 306 patients with ESCC who were treated with RT; EP was observed in 26 patients, with an incidence rate of 8.5%. We observed that age, ECLNIE, esophageal wall thickness, and niche sign by esophagogram before RT were independent risk factors for EP. According to the value of OR in multivariable analyses before PSM, patients with ECLNIE had a higher risk for developing EP. In order to accurately assess the impact of ECLNIE, PSM was conducted to generate 65 pairs of well-matched patients. After PSM, patients with ESCC with ECLNIE had a higher risk of EP (P = 0.002).

ECLNIE was a negative prognostic factor for esophageal carcinoma, which had been reported in some studies. In the study by Tsushima et al, which studied 322 patients with EC, those with ECLNIE had a significantly higher risk for developing EP. Other studies also showed similar findings.[@CIT0015],[@CIT0016] The current study also showed that patients with ESCC with ECLNIE had a higher risk for developing EP. ECLNIE was treated as a risk factor mainly because the lesion had already invaded the adjacent esophageal wall structures, and the fistula was formed after necrosis of the EC and metastasis of the lymph node involving the esophageal wall. Another reason was the imbalance owing to the rapid tumor shrinkage and slow repair of normal tissue during the treatment process. Therefore, special attention should be paid to the ECLNIE, especially in the case of tumors that show a good response. Patients with ESCC with ECLNIE, especially those with rapid tumor regression, should be provided special care and should undergo regular imaging examinations including thoracic CT and iodine oil examination during RT in order to prevent EP.

In addition to ECLNIE, the T stage was reported as another risk factor for EP in some retrospective studies. Watanabe et al[@CIT0017] showed that 20 out of 138 patients with ESCC with stage T3--4 who received definitive CRT developed EP; however, none of the patients with ESCC stage T1--2 developed EP. Chen et al[@CIT0015] studied 322 patients with ESCC and demonstrated that the T4 stage was an independent risk factor for EP; patients at T4 stage showed significantly increased chances of EP. However, a study by Tsushima et al[@CIT0016] revealed that T stage was not a risk factor for EP. In our study, although the T4 stage was correlated with the development of EP, no statistical significance was observed in the multivariable analysis. However, the study revealed that esophageal thickness was an independent risk factor for EP. Thus, patients with ESCC stage T4 without thick esophageal lesions are less likely to develop esophageal fistula.

Some studies revealed that nutritional status prior to treatment had a crucial impact on the formation of EP during and after RT for EC. Poor systemic nutritional status was found to be significantly associated with the increased incidence rate of EP. A study by Watanabe et al[@CIT0017] on 206 patients with EC who underwent revealed that patients at ESCC stage T3 or T4 who had a low BMI (\<20 kg/m^2^), a well-known nutrition-based factor, had an increased risk of developing EP during and after RT. Another study by Singh et al[@CIT0018] on 52 patients with EP demonstrated that patients with lower serum albumin had higher mortality rate than that of patients with higher serum albumin, which was similar to the findings of the study by Burnett et al.[@CIT0019] In our study, PNI and BMI were significantly associated with EP in the univariate analysis, but they were not independent risk factors according to the multivariable analysis. Therefore, although the nutritional status of patients with ESCC affects EP, it is not the main cause of EP. Improving the nutritional status of high-risk patients could reduce the occurrence of EP.

This study has some limitations. Firstly, the sample size of this study was small. A larger number of cases are required to verify the study findings. Secondly, the retrospective nature of the study reduced the overall validity of our results. Thirdly, the sample size of patients with EP was also small owing to the low incidence rate of EP. Despite the abovementioned limitations, this study was the first to conduct PSM to balance the baseline characteristics and adjust for indication biases to assess the impact of ECLNIE in EP. ECLNIE could be considered a reliable risk factor for EP to avoid EP during and after RT.

Conclusion {#S0005}
==========

Overall, patients with ECLNIE have a higher risk of developing EP during and after RT. Thus, patients at a high risk of EP should be provided special attention and care, and attention should be paid to the selection of optimal treatment methods for these patients. Larger-scale studies in this regard are warranted.

The authors thank all patients who participated in the study.
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